Cellestia Biotech

OverviewSuggest Edit

Cellestia Biotech is a biopharmaceutical company with strategic focus on anti-cancer drugs modulating the NOTCH signaling pathway. Its pipeline is supported by the research in the field of oncology and cancer stem cells biology. Cellestia is engaged in the development of mechanisms-based targeted therapeutics to address unmet medical needs, with an emphasis on oncology and immunological disorders. Its anti-cancer CB-103 is a novel, oral pan-NOTCH inhibitor for treatment of NOTCH dependent leukemia, lymphoma and solid tumors.
TypePrivate
Founded2014
HQBasel, CH
Websitecellestia.com

Latest Updates

Employees (est.) (Feb 2017)6
Cybersecurity ratingAMore

Key People/Management at Cellestia Biotech

Michael Bauer

Michael Bauer

CEO
Maximilien Murone

Maximilien Murone

COO
Gaudenz von Capeller

Gaudenz von Capeller

CFO
Raj Lehal

Raj Lehal

Co-Founder, Cellestia Biotech S.A.
Florian Vogl

Florian Vogl

Chief Medical Officer
Guido Guidi

Guido Guidi

Chairman of the Board
Show more

Cellestia Biotech Office Locations

Cellestia Biotech has offices in Basel and Epalinges
Basel, CH (HQ)
60C Hochbergerstrasse
Epalinges, CH
Route de la Corniche 5
Show all (2)

Cellestia Biotech Financials and Metrics

Summary Metrics

Founding Date

2014

Cellestia Biotech total Funding

$48.6 m

Cellestia Biotech latest funding size

$20.39 m

Time since last funding

a year ago

Cellestia Biotech investors

Cellestia Biotech's latest funding round in December 2019 was reported to be $20.4 m. In total, Cellestia Biotech has raised $48.6 m
Show all financial metrics

Cellestia Biotech Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Cellestia Biotech Online and Social Media Presence

Embed Graph

Cellestia Biotech Blogs

Article in “The Swiss Startup Ecosystem: Innovation in Chemistry and the Life Sciences”

Cellestia article “Notch Inhibition in Cancer: Challenges and Opportunities” has been published in “The Swiss Startup Ecosystem: Innovation in Chemistry and the Life Sciences” To read the article click here The post Article in “The Swiss Startup Ecosystem: Innovation in Chemistry and the Life Scienc…

Cellestia presented promising clinical data of its lead compound CB-103 at ESMO 2020

Cellestia Biotech AG presented the first clinical data of its lead compound CB-103 at the virtual congress of the European Society for Medical Oncology (ESMO). To read Cellestia’s press release click here. Esmo 2020 Cellestia Poster   The post Cellestia presented promising clinical data of its lead …

Cellestia Biotech Frequently Asked Questions

  • When was Cellestia Biotech founded?

    Cellestia Biotech was founded in 2014.

  • Who are Cellestia Biotech key executives?

    Cellestia Biotech's key executives are Michael Bauer, Maximilien Murone and Gaudenz von Capeller.

  • How many employees does Cellestia Biotech have?

    Cellestia Biotech has 6 employees.

  • Who are Cellestia Biotech competitors?

    Competitors of Cellestia Biotech include Bellerophon Therapeutics, Deciphera Pharmaceuticals and UNITY Biotechnology.

  • Where is Cellestia Biotech headquarters?

    Cellestia Biotech headquarters is located at 60C Hochbergerstrasse, Basel.

  • Where are Cellestia Biotech offices?

    Cellestia Biotech has offices in Basel and Epalinges.

  • How many offices does Cellestia Biotech have?

    Cellestia Biotech has 2 offices.